Stimulants wake the brain—until the dose tips too far
From caffeine and nicotine to cocaine and amphetamine, stimulants raise alertness by goosing sympathetic nerves and excitatory transmitters. Low prescribed doses can sharpen focus; higher ones may blur it—a twist of the well-known Yerkes–Dodson performance law.
Stimulants—also called central nervous system stimulants, psychostimulants, or uppers—are psychoactive drugs that increase alertness and may lift attention, motivation, mood, and physical activity. Some are natural, some synthetic. Common examples include caffeine, nicotine, cocaine, amphetamine, methamphetamine, methylphenidate, and modafinil. Many raise synaptic norepinephrine and dopamine; nicotine binds excitatory receptors; caffeine blocks sleep-promoting adenosine. Psychostimulants such as amphetamine, methylphenidate, cocaine, and modafinil act at the dopamine transporter, either blocking reuptake or reversing transport. Effects span mild stimulation to euphoria depending on drug, dose, route, and the person.
Medical uses cover ADHD, narcolepsy, obesity, depression, fatigue, nasal congestion, and historically asthma; cocaine also served as a local anesthetic. Archaeological traces of cocaine use in Peru reach about 8000 BCE. Amphetamines treated depression from the 1930s until conventional antidepressants arrived in the 1950s, with renewed interest since. Continuous stimulant antidepressants give fast but short-lived mood lifts and invite tolerance and dependence; withdrawal can mimic major depression. At ADHD doses, focus and sociability may rise; higher doses can worsen focus. Ephedrine, amphetamine, and methylphenidate show ergogenic (performance) benefits; cocaine does not. Cognitive-enhancement findings in healthy people remain mixed and poorly replicated.
Regulation exists because risks include addiction, tolerance, withdrawal, psychosis, anxiety, insomnia, cardiovascular strain, and neurotoxicity. Acute toxicity can bring panic, paranoia, aggression, hyperthermia, arrhythmias, seizures, or worse—lethal dose is hard to pin down. A 2022 meta-analysis of nearly four million people found no link between prescription stimulants and cardiovascular disease across ages, while ADHD treatment reviews note appetite suppression and other adverse events alongside symptom benefit. Abuse of cocaine or methamphetamine raises stroke, infection, and—for meth—Parkinson risk via dopamine neuron damage. In 2015, past-year global use estimates were about 0.4 percent for cocaine, 0.7 percent for amphetamines and prescription stimulants, and 0.4 percent for MDMA.
Source: Stimulant
